genomics

Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications

Six startups from Indonesia, Ireland, Israel, South Africa, United Kingdom and the United States will receive seed investment and access to technology and expertise
Press Release

SAN DIEGO, September 14, 2022 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is a world-class company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. The program also announced today the October 1, 2022 application deadline for its next funding cycle.

Minderoo Foundation and Illumina Commit $40M AUD To Apply Advanced Genomics to Marine Conservation

New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods
Press Release

SAN DIEGO, August. 17, 2022 /3BL Media/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will leverage the power of genomics to accelerate scientific understanding of marine systems and help marine conservationists make informed decisions. The three-year partnership demonstrates a shared commitment to conserving marine biodiversity and understanding the changing marine ecosystems on which people and national economies depend.

Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics

Speakers will outline critical steps needed to achieve health equity
Press Release

SAN DIEGO, August 19, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health. In addition, IGF will host a panel session titled "Making 'Genomics for All' More than a Mantra," on the requirements needed to ensure broader access to genomic health.

The Future Is Bright Campaign Expands Into China

Illumina and Cold Spring Harbor Asia DNA Learning Center reach more than 1,000 STEM learners through a new program
Article

July 1, 2022 /3BL Media/ - Every year for DNA Day in April, Illumina teams organize “The Future Is Bright” activities around the world to inspire students’ STEM learning through community partners and educators teaching genomics in their classrooms. This year, the company partnered with Cold Spring Harbor Asia DNA Learning Center to expand these activities into China for the first time.

AI Drives Data Insights for Doctors and Their Patients

How artificial intelligence and automation are enabling precision medicine to become the standard of care
Article

Dr. Lina Basel-Salmon has been treating rare disease patients at Schneider Children’s Medical Center of Israel and Beilinson Hospital at the Rabin Medical Center for 22 years. In the city of Petah Tikva where she practices, Dr. Basel-Salmon was an early adopter of genomics in clinical practice, using whole-genome sequencing to diagnose her patients. Dr.

Illumina Expands STEM Education Efforts at BizTown Opening

This week, we were the first life science company to join San Diego’s McGrath Family Junior Achievement BizTown
Article

On May 31, Illumina celebrated the official opening of the newest storefront in The McGrath Family Junior Achievement (JA) BizTown, in San Diego, California. Biztown is JA’s experiential-based elementary school capstone program. “Through active participation in a simulated community, students develop an understanding of business, economics, and innovation in San Diego,” said Siddhartha Vivek, President & CEO of Junior Achievement of San Diego.

PRECISE-ILLUMINA Partnership Agreement

Singapore launches Southeast Asia’s most comprehensive consented population study with 100,000 whole genomes for health and clinical breakthroughs
Summary: 

Unique large-scale population study will yield insights into Asian-specific diseases, improving population health, patient outcomes, and innovations in the local biomedical technology industry.

Press Release

Unique large-scale population study will yield insights into Asian-specific diseases, improving population health, patient outcomes, and innovations in the local biomedical technology industry.

Illumina and Deerfield Management Partner to Accelerate Drug Development

First-of-its-kind partnership will identify drug targets and accelerate novel therapy development using genomics and artificial intelligence
Press Release

SAN DIEGO, May 5, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs. The partnership aims to leverage genomic tools and genetic knowledge to select programs with a higher probability of success in order to lower research and development costs and accelerate the approval of cutting-edge therapies.

How Collaboration Is Driving the Next Wave of Genomics

Illumina’s Open Innovation programs work with partners to change lives
Article

BY FASTCO WORKS

RESHAPING MEDICINE

Illumina’s advances in genetic sequencing are reshaping medicine. Genetic sequencing has now allowed cancer patients to find treatment options specific to their tumors, doctors to anticipate adverse drug reactions and personalize medicine, public health agencies around the world to track and detect new COVID variants, and patients with rare diseases to more easily identify and treat their illnesses.

Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children

Hannover Medical School study will evaluate the use of whole-genome sequencing to show positive impact of earlier diagnosis and treatment for children with suspected genetic disorders
Press Release

SAN DIEGO, April 25, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced an agreement with Germany's Hannover Medical School (Medizinische Hochschule Hannover (MHH)) to implement the use of whole-genome sequencing (WGS) in critically ill children suspected of having a genetic or rare disease.

Pages

Subscribe to genomics